Status:
COMPLETED
A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers
Lead Sponsor:
Medikine, Inc.
Collaborating Sponsors:
Medikine Australia Pty Ltd.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
MDK-703-101 is a single ascending dose study, to determine the safety, tolerability, and PK/PD of MDK-703 in healthy adult subjects.
Eligibility Criteria
Inclusion
- 1\. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs.
Exclusion
- 1\. Significant history or clinical manifestation of any metabolic, autoimmune, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.
Key Trial Info
Start Date :
June 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT05366634
Start Date
June 30 2022
End Date
December 28 2022
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medikine Clinical Site
Herston, Queensland, Australia